HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program

Stock News

10/31

FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.

Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1177679917"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177679917\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177679917?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177679917","market":"us","top_or_hot":-1,"title":"HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program","media":"Stock News","content":"<p>FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.</p>\n<p>Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | FUSEN PHARM (01652) Surges Nearly 74% Intraday as Enzalutamide Soft Capsule Approved and Metformin Empagliflozin Tablet Included in National Bulk-Buy Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-31 10:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.</p>\n<p>Additionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01652","symbol_name":"福森药业","start_time":0,"source_url":"","article_id":"1177679917","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177679917","pubTimestamp":1761878056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01652":"福森药业","BK1191":"制药"},"translate_title":"港股动向|福森药业(01652)盘中大涨近74%因恩杂鲁胺软胶囊获批、二甲双胍恩格列净片纳入国家带量采购计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"FUSEN PHARM (01652) surged nearly 74% intraday, and as of the latest update, the stock was up 49.28% at HKD 1.03, with a turnover of HKD 10.37 million. The company announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) for its Enzalutamide Soft Capsule. The drug is approved for treating adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and show no or mild symptoms without prior chemotherapy.\nAdditionally, FUSEN PHARM disclosed that its Metformin Empagliflozin Tablet (I) (containing 500mg metformin hydrochloride and 5mg empagliflozin) has been preliminarily selected in China's 11th national bulk drug procurement program. The company had previously announced in September that the NMPA had approved the market application for this product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}